Publicaciones en colaboración con investigadores/as de Universidad CEU Cardenal Herrera (18)

2023

  1. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2022

  1. Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease

    Pharmaceutics, Vol. 14, Núm. 9

2020

  1. Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis

    Molecules, Vol. 25, Núm. 6

  2. Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells

    Molecules, Vol. 25, Núm. 17

  3. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis

    International Journal of Pharmaceutics, Vol. 588

  4. Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases

    ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660

2019

  1. Technology-enhanced learning in higher education: How to enhance student engagement through blended learning

    European Journal of Education, Vol. 54, Núm. 2, pp. 273-286

2018

  1. Applying loop-mediated isothermal amplification (LAMP) in the diagnosis of malaria, leishmaniasis and trypanosomiasis as point-of-care tests (POCTs)

    Current Topics in Medicinal Chemistry, Vol. 18, Núm. 16, pp. 1358-1374

  2. New drugs and therapeutic/diagnostic targets for fungal and parasitic diseases - part I

    Current Topics in Medicinal Chemistry

  3. New drugs and therapeutic/diagnostic targets for fungal and parasitic diseases - part II

    Current Topics in Medicinal Chemistry

  4. Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 124, pp. 13-27

  5. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis

    Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583

2017

  1. Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106

  2. Engineering synergistically active and bioavailable cost-effective medicines for neglected tropical diseases; the role of excipients

    Current Topics in Medicinal Chemistry, Vol. 17, Núm. 25, pp. 2888-2900

2016

  1. Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals

    European Journal of Pharmaceutical Sciences, Vol. 89, pp. 125-136

2015

  1. Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

    Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431

2014

  1. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp

    International Journal of Pharmaceutics, Vol. 473, Núm. 1-2, pp. 148-157

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46